



12th February, 2025

To

BSE Limited
Corporate Relationship Department
P J Towers
Dalal Street, Fort
Mumbai – 400 001.

Dear Sir/Madam,

Sub: Outcome of Board Meeting held on 12th February, 2025

Ref: Security Code: 524520; Security ID: KMCSHIL

In terms of provisions of Regulation 30 (read with Part A of Schedule III) and Regulations 33 and 52 of SEBI (LODR) Regulations 2015, the Board of Directors at its meeting held today, 12th February 2025, have inter-alia, approved the Standalone Unaudited Financial results for the Quarter and nine months ended 31st December, 2024 along with the Limited Review Report of the Auditors, copy of which is enclosed for your records.

We hereby inform you that the Board Meeting commenced at 10:30 am and concluded at 11:35 a.m

Thank You

With regards,

For **KMC SPECIALITY HOSPITALS (INDIA) LIMITED**



Dr S Manivannan
Managing Director
DIN: 00910804



Regd. Office :

KMC Speciality Hospitals (India) Ltd

CIN - L85110TN1982PLC009781

No. 6, Royal Road, Cantonment, Trichy - 620 001.

T 0431 - 4077777 F 0431 - 2415402

E info@kauveryhospital.com W www.kauveryhospital.com

**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM UNAUDITED
FINANCIAL RESULTS**

TO THE BOARD OF DIRECTORS OF KMC SPECIALITY HOSPITALS (INDIA) LIMITED

1. We have reviewed the accompanying Statement of Unaudited Financial Results of **KMC Speciality Hospitals (India) Limited** (the "Company"), for the quarter and nine months ended December 31, 2024 (the "Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **Deloitte Haskins & Sells**
Chartered Accountants
(Firm's Registration No. 008072S)



Rekha Bai

Rekha Bai
(Partner)
(Membership No. 214161)
(UDIN: 25214161BMIQK E3964)

Place: Chennai
Date: February 12, 2025

KMC Speciality Hospitals (India) Limited
Registered Office: 6, Royal Road, Cantonment, Trichy - 620 001
Corporate Identity Number: L85110TN1982PLC009781

Statement of Unaudited financial results for the quarter and nine months ended December 31, 2024

(Rs. in Lakhs except EPS)

Particulars	Quarter ended			Nine months ended		Year ended
	December 31, 2024 (Unaudited)	September 30, 2024 (Unaudited)	December 31, 2023 (Unaudited)	December 31, 2024 (Unaudited)	December 31, 2023 (Unaudited)	March 31, 2024 (Audited)
1 Income						
a) Revenue from operations	6,136.41	5,623.07	4,912.09	17,066.28	13,228.39	17,717.53
b) Other income	121.43	45.91	57.51	229.43	278.74	355.99
Total income	6,257.84	5,668.98	4,969.60	17,295.71	13,507.13	18,073.52
2 Expenses						
a) Cost of materials consumed	251.97	247.62	101.86	683.69	268.31	358.66
b) Purchases of stock-in-trade	640.93	568.65	564.67	1,796.85	1,569.10	2,066.97
c) Change in inventories of stock in trade	(12.99)	(4.27)	(51.17)	(81.72)	(30.32)	16.80
d) Employee benefits expense	1,356.50	1,299.07	1,003.09	3,912.02	2,815.67	3,826.71
e) Finance costs	232.96	269.33	24.33	710.32	66.62	116.39
f) Depreciation and amortisation expense	484.95	495.24	225.31	1,388.19	658.75	922.36
g) Other expenses	2,298.70	2,259.83	1,852.68	6,588.36	5,045.59	6,709.81
Total expenses	5,253.02	5,135.47	3,720.77	15,017.71	10,393.72	14,017.70
3 Profit before tax (1-2)	1,004.82	533.51	1,248.83	2,278.00	3,113.41	4,055.82
4 Income tax expense						
a) Current tax	303.11	163.41	313.21	597.19	819.64	877.33
b) Deferred tax	(49.67)	(18.31)	(13.12)	(9.70)	(35.56)	140.56
Total income tax expense	253.44	145.10	300.09	587.49	784.08	1,017.89
5 Profit for the period (3-4)	751.38	388.41	948.74	1,690.51	2,329.33	3,037.93
6 Other comprehensive income / (loss)						
Items that will not be reclassified subsequently to profit or loss						
(a) Re-measurement of defined benefit plans	(5.96)	(1.85)	(9.68)	(17.89)	(29.05)	(40.32)
(b) Income tax relating to items that will not be reclassified to statement of profit or loss	1.50	0.46	2.43	4.50	7.31	10.15
Total other comprehensive income / (loss), net of tax	(4.46)	(1.39)	(7.25)	(13.39)	(21.74)	(30.17)
7 Total comprehensive income (5+6)	746.92	387.02	941.49	1,677.12	2,307.59	3,007.76
8 Paid-up equity share capital (Face value of Re. 1/- each)	1,630.85	1,630.85	1,630.85	1,630.85	1,630.85	1,630.85
9 Reserves i.e. Other equity						12,727.12
10 Earnings per share (EPS) of Re. 1/- each :						
Basic	0.46	0.24	0.58	1.04	1.43	1.86
Diluted	0.46	0.24	0.58	1.04	1.43	1.86
	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Annualised)

Notes:

- These above unaudited financial results of KMC Speciality Hospitals (India) Limited ("the Company") for the quarter and nine months ended December 31, 2024 are prepared in accordance with Indian Accounting Standard ('Ind AS') as prescribed under section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended.
- The above results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors in their meetings held on February 11, 2025 and February 12, 2025 respectively. The results for the quarter and nine months ended December 31, 2024 has been reviewed by our statutory auditors. The statutory auditors have issued an unmodified review report for the quarter and nine months ended December 31, 2024.
- The Company operates in a single segment i.e. "Medical and Healthcare Services" and hence does not have any additional disclosures to be made under IND AS 108 - "Operating Segments".



Place: Chennai
Date: February 12, 2025

For and on behalf of the board of directors of
KMC Speciality Hospitals (India) Limited
CIN: L85110TN1982PLC009781

